{"success":true,"data":{"pressRelease":{"id":"154831","rtpr_id":"nNFC1YlMY7-20260929","ticker":"VIVI","exchange":"","all_tickers":["VIVI"],"title":"TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus","author":"Newsfile Corp","published_at":"2026-09-29T07:05:15.609Z","article_body":"Distribution partnership with one of Cyprus's most established healthcare and\nconsumer-products distributors\n\nHighlights:\n* LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI\nEpi™ throughout Cyprus, subject to a definitive agreement.\n* Proposed exclusivity is conditional on minimum annual purchase obligations,\nwith combined purchases required to increase by at least 20% year over year to\nmaintain exclusivity.\n* Transfer pricing and the first-year minimum combined unit commitment will be\nnegotiated and established in the definitive distribution agreement.\n* CPO Cyprus brings nearly a century of local market experience and\nestablished distribution capabilities spanning pharmaceutical products,\nmedical instruments and hospital equipment.\nToronto, Ontario--(Newsfile Corp. - September 29, 2026) - TempraMed\nTechnologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (\"TempraMed\" or the\n\"Company\"), a medical-technology innovator transforming how\ntemperature-sensitive medications are stored and managed, is pleased to\nannounce that it has signed a non-binding letter of intent (the \"LOI\") dated\nJuly 31, 2026 with Cyprus Pharmaceutical Organization Ltd. (\"CPO Cyprus\")\nregarding the proposed exclusive distribution of VIVI Cap™ and VIVI Epi™\nin Cyprus.\n\nUnder the LOI, TempraMed proposes to appoint CPO Cyprus as the exclusive\ndistributor of VIVI Cap and VIVI Epi in Cyprus, subject to the execution of a\ndefinitive distribution agreement and CPO Cyprus's compliance with minimum\npurchase obligations. The specific transfer prices and first-year minimum\ncombined unit commitment have not yet been finalized and are to be established\nin the definitive agreement.\n\nTo maintain the proposed exclusivity, CPO Cyprus would be required to increase\nits total annual combined purchases of VIVI Cap and VIVI Epi by no less than\n20% year over year. The LOI provides a 90-day period from July 31, 2026 for\nthe parties to negotiate and conclude a definitive agreement, unless extended\nby mutual agreement.\n\nCPO Cyprus was founded in Nicosia in 1928 and, according to CPO Group, has\ngrown to rank among the 20 largest trading firms in Cyprus. The company is an\nimporter, distributor and exclusive agent across the health, beauty,\npersonal-care and food sectors, with products ranging from pharmaceuticals to\nspecialized medical instruments and hospital equipment.\n\nTempraMed believes CPO Cyprus's healthcare-market experience, established\nlocal relationships and distribution capabilities make it a strong prospective\npartner for the Company's entry into Cyprus.\n\nThe proposed relationship supports TempraMed's strategy of expanding through\nexperienced local partners that can navigate country-specific healthcare\nchannels and build sustained product adoption. If a definitive agreement is\ncompleted, Cyprus would become an additional European market for two of\nTempraMed's commercial medication-protection products.\n\n\"CPO Cyprus is exactly the kind of established, market-facing partner we want\nas we expand TempraMed's global commercial footprint,\" said Ron Nagar, Founder\nand CEO of TempraMed. \"With roots in Cyprus dating back nearly a century and\nbroad experience across pharmaceutical and medical-product distribution, CPO\nCyprus offers a strong prospective platform for introducing VIVI Cap and VIVI\nEpi nationwide. The proposed annual purchase-growth requirement reflects our\nintention to build this relationship for scale. We are focused on converting\nthis LOI into a definitive agreement and, subject to completing that agreement\nand satisfying all applicable requirements, making Cyprus another meaningful\nmarket for TempraMed. This planned expansion further demonstrates the\ninternational relevance of our passive, battery-free technology for people who\nrely on temperature-sensitive medications.\"\n\nAbout CPO Cyprus\n\nFounded in Nicosia in 1928 as C.A. Papaellinas & Co. and renamed Cyprus\nPharmaceutical Organization in 1952, CPO Cyprus is the largest subsidiary of\nCPO Group and has grown to be among the 20 largest trading firms in Cyprus.\nThe company operates as an importer, distributor and exclusive agent in the\nhealth, beauty, personal-care and food sectors. Its portfolio ranges from\nmass-market and pharmaceutical products to specialized medical instruments and\nhospital equipment. For more information, visit www.cpogroup.cy.\n\nAbout TempraMed Technologies Ltd.\n\nTempraMed Technologies Ltd. is a global medical-device company with a\nportfolio of innovative, temperature-controlled medication-storage solutions.\nFounded with the mission to safeguard the effectiveness of life-saving\nmedications, TempraMed develops patented, FDA-registered thermal-insulation\ndevices that operate continuously without batteries or external power. Its\ncommercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI\nEpi™ and VIVI Med™. TempraMed enables patients and healthcare providers to\nconfidently manage temperature-sensitive medications anywhere, anytime.\n\nInvestors interested in learning more about TempraMed are encouraged to\ncontact the Company at:\n\nir@tempramed.com \nwww.tempramed.com\n\nContact:\n\nJulia Becker\nVice President, Capital Markets\nT: +1 (604) 785-0850\nE: julia@tempramed.com\n\nMedia:\nBrenda Zeitlin\nVice President, Marketing\nE: brenda@tempramed.com\n\nCautionary Statements\n\nTHE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT\nRESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES\nTHE CSE'S REGULATION SERVICES PROVIDER.\n\nThis press release contains \"forward-looking information\" and \"forward-looking\nstatements\" within the meaning of applicable Canadian securities legislation.\nForward-looking statements may be identified by words such as \"anticipate,\"\n\"believe,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"should,\"\n\"strategy,\" \"will\" and similar expressions, or statements concerning events or\nconditions that may occur in the future.\n\nForward-looking statements in this press release include, without limitation,\nthe negotiation, execution and timing of a definitive distribution agreement\nwith CPO Cyprus; the terms of any such agreement, including transfer pricing,\nminimum purchase obligations and the conditions of exclusivity; the\nappointment of CPO Cyprus as exclusive distributor of VIVI Cap and VIVI Epi in\nCyprus; the anticipated benefits of the proposed relationship; the Company's\nstrategy of expanding through local distribution partners and its ability to\nenter Cyprus and other European markets; the addition or renewal of\ndistribution agreements in other jurisdictions; regulatory clearance and\nimport requirements for the Company's products in Cyprus; consumer adoption of\nthe Company's products; and the Company's ability to expand its commercial\npresence in Cyprus.\n\nForward-looking statements are based on the opinions, expectations and\nassumptions of management as of the date of this press release, including\nassumptions that the parties will successfully negotiate and execute a\ndefinitive distribution agreement on terms consistent with the LOI; that CPO\nCyprus will satisfy the conditions to exclusivity; that required regulatory\napprovals and import clearances will be obtained; and that demand for\ntemperature-protection solutions for injectable medications will continue.\n\nForward-looking statements are subject to known and unknown risks,\nuncertainties and other factors that may cause actual results to differ\nmaterially from those expressed or implied, including: that the LOI is\nnon-binding and there is no assurance that a definitive agreement will be\nentered into, or, if entered into, that it will be on the terms contemplated\nby the LOI or within the anticipated timeframe; the risk that the parties may\nbe unable to agree on transfer pricing, minimum purchase commitments or other\nmaterial terms; the risk that CPO Cyprus may not meet minimum purchase\nobligations or the 20% annual growth requirement, resulting in loss of\nexclusivity; regulatory approval and import requirements; competitive\ndevelopments; market acceptance; general economic conditions; geopolitical\nrisks; and other risks described in the Company's public filings available on\nSEDAR+.\n\nExcept as required by applicable securities laws, the Company undertakes no\nobligation to update or revise publicly any forward-looking statements.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316370","article_body_html":"","raw_payload":{"data":{"id":"nNFC1YlMY7-20260929","title":"TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus","author":"Newsfile Corp","ticker":"VIVI","created":"2026-09-29T07:05:15.609Z","tickers":["VIVI"],"exchange":"","article_body":"Distribution partnership with one of Cyprus's most established healthcare and\nconsumer-products distributors\n\nHighlights:\n* LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI\nEpi™ throughout Cyprus, subject to a definitive agreement.\n* Proposed exclusivity is conditional on minimum annual purchase obligations,\nwith combined purchases required to increase by at least 20% year over year to\nmaintain exclusivity.\n* Transfer pricing and the first-year minimum combined unit commitment will be\nnegotiated and established in the definitive distribution agreement.\n* CPO Cyprus brings nearly a century of local market experience and\nestablished distribution capabilities spanning pharmaceutical products,\nmedical instruments and hospital equipment.\nToronto, Ontario--(Newsfile Corp. - September 29, 2026) - TempraMed\nTechnologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (\"TempraMed\" or the\n\"Company\"), a medical-technology innovator transforming how\ntemperature-sensitive medications are stored and managed, is pleased to\nannounce that it has signed a non-binding letter of intent (the \"LOI\") dated\nJuly 31, 2026 with Cyprus Pharmaceutical Organization Ltd. (\"CPO Cyprus\")\nregarding the proposed exclusive distribution of VIVI Cap™ and VIVI Epi™\nin Cyprus.\n\nUnder the LOI, TempraMed proposes to appoint CPO Cyprus as the exclusive\ndistributor of VIVI Cap and VIVI Epi in Cyprus, subject to the execution of a\ndefinitive distribution agreement and CPO Cyprus's compliance with minimum\npurchase obligations. The specific transfer prices and first-year minimum\ncombined unit commitment have not yet been finalized and are to be established\nin the definitive agreement.\n\nTo maintain the proposed exclusivity, CPO Cyprus would be required to increase\nits total annual combined purchases of VIVI Cap and VIVI Epi by no less than\n20% year over year. The LOI provides a 90-day period from July 31, 2026 for\nthe parties to negotiate and conclude a definitive agreement, unless extended\nby mutual agreement.\n\nCPO Cyprus was founded in Nicosia in 1928 and, according to CPO Group, has\ngrown to rank among the 20 largest trading firms in Cyprus. The company is an\nimporter, distributor and exclusive agent across the health, beauty,\npersonal-care and food sectors, with products ranging from pharmaceuticals to\nspecialized medical instruments and hospital equipment.\n\nTempraMed believes CPO Cyprus's healthcare-market experience, established\nlocal relationships and distribution capabilities make it a strong prospective\npartner for the Company's entry into Cyprus.\n\nThe proposed relationship supports TempraMed's strategy of expanding through\nexperienced local partners that can navigate country-specific healthcare\nchannels and build sustained product adoption. If a definitive agreement is\ncompleted, Cyprus would become an additional European market for two of\nTempraMed's commercial medication-protection products.\n\n\"CPO Cyprus is exactly the kind of established, market-facing partner we want\nas we expand TempraMed's global commercial footprint,\" said Ron Nagar, Founder\nand CEO of TempraMed. \"With roots in Cyprus dating back nearly a century and\nbroad experience across pharmaceutical and medical-product distribution, CPO\nCyprus offers a strong prospective platform for introducing VIVI Cap and VIVI\nEpi nationwide. The proposed annual purchase-growth requirement reflects our\nintention to build this relationship for scale. We are focused on converting\nthis LOI into a definitive agreement and, subject to completing that agreement\nand satisfying all applicable requirements, making Cyprus another meaningful\nmarket for TempraMed. This planned expansion further demonstrates the\ninternational relevance of our passive, battery-free technology for people who\nrely on temperature-sensitive medications.\"\n\nAbout CPO Cyprus\n\nFounded in Nicosia in 1928 as C.A. Papaellinas & Co. and renamed Cyprus\nPharmaceutical Organization in 1952, CPO Cyprus is the largest subsidiary of\nCPO Group and has grown to be among the 20 largest trading firms in Cyprus.\nThe company operates as an importer, distributor and exclusive agent in the\nhealth, beauty, personal-care and food sectors. Its portfolio ranges from\nmass-market and pharmaceutical products to specialized medical instruments and\nhospital equipment. For more information, visit www.cpogroup.cy.\n\nAbout TempraMed Technologies Ltd.\n\nTempraMed Technologies Ltd. is a global medical-device company with a\nportfolio of innovative, temperature-controlled medication-storage solutions.\nFounded with the mission to safeguard the effectiveness of life-saving\nmedications, TempraMed develops patented, FDA-registered thermal-insulation\ndevices that operate continuously without batteries or external power. Its\ncommercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI\nEpi™ and VIVI Med™. TempraMed enables patients and healthcare providers to\nconfidently manage temperature-sensitive medications anywhere, anytime.\n\nInvestors interested in learning more about TempraMed are encouraged to\ncontact the Company at:\n\nir@tempramed.com \nwww.tempramed.com\n\nContact:\n\nJulia Becker\nVice President, Capital Markets\nT: +1 (604) 785-0850\nE: julia@tempramed.com\n\nMedia:\nBrenda Zeitlin\nVice President, Marketing\nE: brenda@tempramed.com\n\nCautionary Statements\n\nTHE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT\nRESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES\nTHE CSE'S REGULATION SERVICES PROVIDER.\n\nThis press release contains \"forward-looking information\" and \"forward-looking\nstatements\" within the meaning of applicable Canadian securities legislation.\nForward-looking statements may be identified by words such as \"anticipate,\"\n\"believe,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"should,\"\n\"strategy,\" \"will\" and similar expressions, or statements concerning events or\nconditions that may occur in the future.\n\nForward-looking statements in this press release include, without limitation,\nthe negotiation, execution and timing of a definitive distribution agreement\nwith CPO Cyprus; the terms of any such agreement, including transfer pricing,\nminimum purchase obligations and the conditions of exclusivity; the\nappointment of CPO Cyprus as exclusive distributor of VIVI Cap and VIVI Epi in\nCyprus; the anticipated benefits of the proposed relationship; the Company's\nstrategy of expanding through local distribution partners and its ability to\nenter Cyprus and other European markets; the addition or renewal of\ndistribution agreements in other jurisdictions; regulatory clearance and\nimport requirements for the Company's products in Cyprus; consumer adoption of\nthe Company's products; and the Company's ability to expand its commercial\npresence in Cyprus.\n\nForward-looking statements are based on the opinions, expectations and\nassumptions of management as of the date of this press release, including\nassumptions that the parties will successfully negotiate and execute a\ndefinitive distribution agreement on terms consistent with the LOI; that CPO\nCyprus will satisfy the conditions to exclusivity; that required regulatory\napprovals and import clearances will be obtained; and that demand for\ntemperature-protection solutions for injectable medications will continue.\n\nForward-looking statements are subject to known and unknown risks,\nuncertainties and other factors that may cause actual results to differ\nmaterially from those expressed or implied, including: that the LOI is\nnon-binding and there is no assurance that a definitive agreement will be\nentered into, or, if entered into, that it will be on the terms contemplated\nby the LOI or within the anticipated timeframe; the risk that the parties may\nbe unable to agree on transfer pricing, minimum purchase commitments or other\nmaterial terms; the risk that CPO Cyprus may not meet minimum purchase\nobligations or the 20% annual growth requirement, resulting in loss of\nexclusivity; regulatory approval and import requirements; competitive\ndevelopments; market acceptance; general economic conditions; geopolitical\nrisks; and other risks described in the Company's public filings available on\nSEDAR+.\n\nExcept as required by applicable securities laws, the Company undertakes no\nobligation to update or revise publicly any forward-looking statements.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316370"},"type":"article","timestamp":"2026-09-29T07:05:15.669463665Z","server_sent_at_ms":1790665515669},"received_at":"2026-09-29T07:05:15.721Z","source_url":"https://www.newsfilecorp.com/release/316370"},"analysis":{"id":"143585","press_release_id":"154831","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["LOI is non-binding; no assurance a definitive agreement will be signed","commercial terms (transfer pricing, first-year minimums) not yet finalized"],"eventType":"partnership","narrative":"TempraMed signed a non-binding LOI dated July 31, 2026 with CPO Cyprus for exclusive distribution of VIVI Cap and VIVI Epi throughout Cyprus, subject to a definitive agreement.\n\nExclusivity is conditional on CPO Cyprus growing combined annual purchases at least 20% year over year; transfer pricing and the first-year minimum unit commitment remain to be negotiated within a 90-day window.\n\nCPO Cyprus, founded in 1928 and among Cyprus's 20 largest trading firms, would give TempraMed an established channel into another European market for its battery-free medication-storage devices.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap medtech expands European footprint via non-binding Cyprus distribution LOI -- definitive agreement is the real catalyst."},"keyFigures":{"customDimensions":{"loi_negotiation_window_days":90,"exclusivity_growth_requirement":"20% YoY increase in combined annual purchases"}},"quotedText":"CPO Cyprus is exactly the kind of established, market-facing partner we want as we expand TempraMed's global commercial footprint","namedEntities":{"people":[{"name":"Ron Nagar","role":"Founder and CEO of TempraMed"}],"products":["VIVI Cap","VIVI Epi","VIVI Cap Smart","VIVI Med"],"companies":[{"name":"TempraMed Technologies Ltd.","ticker":"VIVI","relationship":"filer"},{"name":"Cyprus Pharmaceutical Organization Ltd. (CPO Cyprus)","relationship":"prospective exclusive distributor"},{"name":"CPO Group","relationship":"parent of CPO Cyprus"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Non-binding LOI for exclusive distribution of VIVI Cap and VIVI Epi in Cyprus, a small new market. Key commercial terms (transfer pricing, first-year minimums) are not finalized and the deal may not close."},"tickerRelevance":{"others":[],"primary":"VIVI"},"globalImportance":15,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"non-binding distribution LOI in small market","marketCapAdjustment":"small company but event is early-stage and unpriced"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"TempraMed signed a non-binding LOI dated July 31, 2026 with CPO Cyprus for exclusive distribution of VIVI Cap and VIVI Epi throughout Cyprus, subject to a definitive agreement.\n\nExclusivity is conditional on CPO Cyprus growing combined annual purchases at least 20% year over year; transfer pricing and the first-year minimum unit commitment remain to be negotiated within a 90-day window.\n\nCPO Cyprus, founded in 1928 and among Cyprus's 20 largest trading firms, would give TempraMed an established channel into another European market for its battery-free medication-storage devices.","key_figures":{"customDimensions":{"loi_negotiation_window_days":90,"exclusivity_growth_requirement":"20% YoY increase in combined annual purchases"}},"named_entities":{"people":[{"name":"Ron Nagar","role":"Founder and CEO of TempraMed"}],"products":["VIVI Cap","VIVI Epi","VIVI Cap Smart","VIVI Med"],"companies":[{"name":"TempraMed Technologies Ltd.","ticker":"VIVI","relationship":"filer"},{"name":"Cyprus Pharmaceutical Organization Ltd. (CPO Cyprus)","relationship":"prospective exclusive distributor"},{"name":"CPO Group","relationship":"parent of CPO Cyprus"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T07:05:21.651Z","global_importance":15,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"non-binding distribution LOI in small market","marketCapAdjustment":"small company but event is early-stage and unpriced"}},"durationMs":5870,"modelName":"glm-5.3-flashx"}}